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Abstract
Purpose Leptomeningeal metastases (LM) are a rare, but often debilitating complication of advanced cancer that can severely 
impact a patient’s quality-of-life. LM can result in hydrocephalus (HC) and lead to a range of neurologic sequelae, includ-
ing weakness, headaches, and altered mental status. Given that patients with LM generally have quite poor prognoses, the 
decision of how to manage this HC remains unclear and is not only a medical, but also an ethical one.
Methods We first provide a brief overview of management options for hydrocephalus secondary to LM. We then apply 
general ethical principles to decision making in LM-associated hydrocephalus that can help guide physicians and patients.
Results Management options for LM-associated hydrocephalus include shunt placement, repeated lumbar punctures, intra-
ventricular reservoir placement, endoscopic third ventriculostomy, or pain management alone without intervention. While 
these options may offer symptomatic relief in the short-term, each is also associated with risks to the patient. Moreover, data 
on survival and quality-of-life following intervention is sparse. We propose that the pros and cons of each option should be 
evaluated not only from a clinical standpoint, but also within a larger framework that incorporates ethical principles and 
individual patient values.
Conclusions The decision of how to manage LM-associated hydrocephalus is complex and requires close collaboration 
amongst the physician, patient, and/or patient’s family/friends/community leaders. Ultimately, the decision should be rooted 
in the patients’ values and should aim to optimize a patient’s quality-of-life.
Keywords Leptomeningeal metastases · Hydrocephalus · Ethics · Shunt · Quality-of-life
Introduction
Leptomeningeal metastases (LM) are being increasingly 
encountered in present-day clinical practice. This greater 
incidence is likely due to advances in the treatment of can-
cer that allow patients to live long enough to develop late 
complications such as LM [1–3]. Yet, despite the progress 
in oncologic treatments, the prognosis for LM remains poor 
with average survival ranging from 3.5 to 6 months [1–4].
LM affects approximately 5–8% of patients with solid 
tumors [5]. Patients with LM typically present with acute 
and often debilitating neurologic symptoms, including head-
aches, nausea, cognitive dysfunction, seizures, cranial nerve 
deficits, and/or weakness and pain [2, 4]. As these symptoms 
greatly affect patients’ quality-of-life [1], it is of importance 
to effectively manage them. Hydrocephalus (HC) secondary 
to LM is common [6], though outcomes in patients with 
metastases-related hydrocephalus are poor with approxi-
mately 10% 1-year survival [4].
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Management of hydrocephalus in patients with LM is 
challenging, as effective, immediate symptom relief often 
requires surgical intervention in frail cancer patients [4]. 
Although the available data exploring the effectiveness of 
ventriculoperitoneal shunt (VPS) placement in improving 
quality-of-life in this patient population is limited, the pro-
cedure is commonly performed to relieve patients of hydro-
cephalus-associated symptoms [1].
There is currently no clear medical consensus for the best 
treatment option to manage LM-associated hydrocephalus. 
We believe this question is less of a medical question and 
more of an ethical one. Given that the prognosis for patients 
with LM can vary based on performance status, systemic 
disease control, age, and primary tumor histology [3, 7], we 
believe that a more nuanced, patient-centered approach to 
managing their hydrocephalus should be undertaken. This 
approach should look not only at the hard facts surrounding 
expected disease course, but combine patient quality-of-life 
measures, cultural values, and fundamental ethical princi-
ples in determining the ideal management option for these 
patients.
Here, we aim to briefly present the current surgical 
options for LM-associated hydrocephalus and the pros and 
cons surrounding each. Subsequently, we will offer ways 
to facilitate physician and patient decision-making based 
on general ethical principles applied to patients with LM-
associated hydrocephalus.
Current surgical options
Current options for management of LM-associated hydro-
cephalus include: (1) shunt placement; (2) repeated lum-
bar punctures; (3) intraventricular reservoir placement; (4) 
endoscopic third ventriculostomy; or (5) no intervention 
with focus on pain management [3, 4].
CSF diversionary procedures: ventroperitoneal 
or lumbar shunting
VPS involves placement of a catheter in the lateral ventri-
cle, connected into the peritoneal cavity [8]. VPS allows for 
rapid normalization of elevated intracranial pressure (ICP) 
and is thus commonly employed to relieve symptoms of 
hydrocephalus [5, 8, 9]. Table 1 depicts studies that have pre-
viously reported symptoms and outcomes for patients with 
leptomeningeal disease-associated HC who have undergone 
shunting. Overall, these retrospective series have demon-
strated significant improvement in hydrocephalus-associated 
symptoms following VPS placement, with rates of symp-
tom improvement ranging from 75 to > 90% (Table 1) [4, 
5, 9–11]. Shunting has also led to marked patient improve-
ments in performance status, with post-surgical Karnofsky 
Performance Status (KPS) increases of 10–20 points [4, 
11]. While it has not been standard-of-care to intervene on 
patients with low performance scores, the minimal published 
data suggests that VPS may improve quality-of-life even in 
patients with low KPS [9, 10].
Despite the symptomatic relief following VPS expe-
rienced by many patients, there are gradations of benefit 
based upon various patient factors. For example, it appears 
that while headache and nausea are most likely to improve 
following VPS, results are variable with respect to cogni-
tive dysfunction, urinary incontinence, and gait dysfunc-
tion [9, 11]. Moreover, per the results of Murakami et al., 
only patients with a presenting KPS ≥ 30 benefited from 
VPS. In contrast, those with a KPS < 30 before surgery 
died within 1 month of their procedure due to worsening of 
their general condition [4]. In addition, while prior studies 
have shown that in general, patients with LMD from breast 
cancer, leukemia, and  lymphoma tend to have slightly 
improved survival compared to LMD from other primary 
tumor sites [12, 13], the studies in Table 1 that focused on 
patients with LMD-associated hydrocephalus did not find 
primary tumor histology to be prognostic for survival [5, 
11]. However, the improvement in symptoms following 
VPS did allow for subsequent administration of systemic 
therapies in some cases, possibly contributing to increased 
survival [1, 11]. These results suggest that in patients with 
primary tumors for which systemic therapies are available, 
alleviation of debilitating symptoms via placement of a 
shunt may allow for more rigorous treatment.
VPS also poses potential risks, including infection, 
bleeding, and peritoneal tumor dissemination, although 
none of the studies in Table 1 found any cases of perito-
neal carcinomatosis after VPS [1, 5]. These studies have 
demonstrated complication rates between 9 and 19% [5, 
9, 10], often leading to a second surgery for shunt revision 
[4, 5, 11].
As seen in Table 1, the data on outcomes following 
VPS in patients with LMD is sparse, and there is thus no 
obvious paradigm for clinicians to follow when recom-
mending shunt surgery for LM-associated hydrocephalus. 
Even after VPS, median survival across studies remains 
low, ranging from 2 to 7.5 months (Table 1). Only one 
prior study had a “non-surgical” group to compare to the 
shunted patients, and while there was improved survival 
in the group that underwent shunting, this difference was 
non-significant, and there was also no data on symptom 
relief or quality-of-life to compare across the two groups. 
Thus, while those with severe presenting symptoms of 
headaches and nausea may derive the greatest benefit, 
more conservative approaches may be suitable for those 
with cognitive symptoms that are unlikely to improve or 
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those with very low KPS. In addition, in the studies that 
did report on complications, the risks were non-negligible, 
and often led to revision surgery, which might pose signifi-
cant challenges in a population of patients that is seriously 
ill and with poor reserve to begin with.
Repeated lumbar punctures or placement 
of intraventricular reservoir
Other potential options for relieving elevated ICP secondary 
to hydrocephalus involve repeated lumbar punctures (LPs) or 
the placement of an intraventricular reservoir [3, 15]. While 
typically performed to obtain CSF for diagnostic purposes, 
LPs have also been shown to result in rapid improvement of 
acute symptoms secondary to hydrocephalus [8, 16]. How-
ever, serial LPs are not ideal as they subject patients to the 
constant discomfort of repeated intervention.
Intraventricular reservoirs, in contrast, work similarly to 
LPs, but are less imposing on patients. Such reservoirs are 
placed underneath the scalp in the frontal horn of the right 
lateral ventricle; a connecting catheter allows for commu-
nication between the device and CSF. Generally used for 
delivery of intrathecal chemotherapy in patients with lep-
tomeningeal disease (LMD), they can also allow for CSF 
aspiration in the setting of high ICP [15, 17]. Compared to 
LPs, repeated access to CSF is easier and more comfortable 
for patients with a reservoir.
However, reservoirs also come with possible complica-
tions, including infection, hemorrhage, or malpositioning 
[8, 17]. Malpositioning rates range from 2.7 to 12.5% and 
can have serious consequences [8, 17, 18]. If a patient with 
hydrocephalus is not receiving chemotherapy, the utility 
for such an intervention compared to more permanent solu-
tions must be weighed against the burden of an additional 
procedure that may eventually require conversion to a more 
sustainable solution anyways.
Endoscopic third ventriculostomy
LMD can present with either obstructive or non-obstructive 
hydrocephalus [5]; while VPS remains the preferred treat-
ment in patients with non-obstructive hydrocephalus, endo-
scopic third ventriculostomy (ETV) may be another potential 
therapeutic option in those with obstructive hydrocephalus 
[17, 19]. ETV involves the endoscopic placement of a small 
hole at the floor of the third ventricle that subsequently 
allows for diversion of CSF into the interpeduncular cis-
tern [17, 20]. It is minimally invasive, has a low operative 
morbidity, and is generally less uncomfortable for patients 
compared to VPS [19, 21]. LMD impairs CSF resorption 
capacity, and ETV would therefore not be expected to be 
efficacious in such cases of communicating HC [19]. The use 
of ETV in patients with LMD-associated hydrocephalus has 
therefore not been well-studied, although a few reports have 
looked at its role in patients with hydrocephalus secondary 
to parenchymal brain metastases [10, 19, 21]. These studies 
have demonstrated symptom improvement rates of ~ 70% in 
these patients, with lower or similar complication rates as 
compared to those following VPS [10, 19, 21].
One study triaged patients with hydrocephalus second-
ary to cerebral metastasis to either VPS or ETV based 
upon whether they had non-obstructive or obstructive 
hydrocephalus, respectively, and showed similar clinical 
outcomes in terms of symptom palliation, post-operative 
KPS improvement, and overall survival between the two 
groups [10]. While the difference in the overall complica-
tion rate between the two groups did not reach statistical 
significance, VPS patients had a greater complication rate 
of 19.4 versus 12.6% in the ETV group [10]. These results 
suggest that in patients with metastasis-related, obstructive 
hydrocephalus, the less invasive option of ETV might offer 
a similar degree of benefit to patients as VPS, but without 
as many complications. While the aforementioned stud-
ies did not assess a role for ETV in patients with LMD, 
their results suggest ETV may be an effective option when 
hydrocephalus is secondary to bulky LMD impairing 
CSF outflow [5]. Each patient’s radiographic abnormali-
ties should thus be studied to determine the cause of the 
hydrocephalus and subsequently to determine whether 
ETV might be a more suitable option than VPS in these 
patients. Overall, further study of ETV in patients with 
LMD is warranted.
Non‑intervention
Patients may also opt not to treat their hydrocephalus. While 
the above studies demonstrate the effectiveness of surgical 
intervention on immediate symptom relief, the prognosis 
even after treatment of metastasis-related hydrocephalus 
remains poor [9]. Thus, the burden of an additional inter-
vention may not be desirable. Median survival in patients 
with untreated LM ranges from 1 to 2 months, sometimes 
extending to 6 months in aggressively-treated populations 
[21–24]. While many of these patients die from progression 
of their systemic cancer [25], per some reports in the litera-
ture, the majority of deaths in this patient population occur 
due to progressive neurological involvement of the patients’ 
disease [22, 23], underscoring the importance of determin-
ing whether neurosurgical intervention is justified if it is the 
neurological sequelae that are leading to patient death. A 
study by Jung et al. explored the prognostic significance of 
surgically treated hydrocephalus in LM and found improved 
overall survival in surgically treated hydrocephalus as com-
pared to surgically untreated hydrocephalus (median 5.7 
versus 1.7 months), although this did not reach statistical 
10 Journal of Neuro-Oncology (2018) 140:5–13
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significance [24]. While this study did not evaluate quality-
of-life or quality-of-death, studies should assess the comfort 
and pain levels of patients who live longer following surgi-
cal intervention for hydrocephalus. This information could 
allow clinicians and patients to better weigh the risks and 
benefits of intervention versus non-intervention.
Ethics of intervention
The lack of clear medical consensus on how to manage LM-
associated hydrocephalus likely stems from a lack of robust 
data, as well as wide variation in patient presentation, belief 
systems, and environmental resources. Together, these make 
it difficult to recommend a general paradigm applicable to 
all patients. Patients’ prognoses differ based upon prior and 
concurrent treatments, performance status, systemic disease 
burden, primary tumor histology, and other factors [3, 7]. 
Still, most patients with LM tend to be seriously ill and gen-
erally have poor prognoses. This complicates the decision 
to actively intervene at the risk of exposing the patient to 
further complications versus focusing on comfort measures 
alone.
As mentioned above, there is data to suggest prolonged 
survival following treatment of LM-associated hydrocepha-
lus [24]. However, assessment of patient QOL during this 
extended survival period is lacking. Moreover, given that 
even after the surgery, median survival is still on the order 
of months, we think that fundamental ethical principles as 
opposed to statistics can better guide decision-making.
Beauchamp and Childress have previously proposed a 
four-principles approach to medical ethics, highlighting 
the following ethical principles: respect for autonomy; non-
maleficence; beneficence; and justice [26]. Below, we will 
briefly define these principles and apply them to LM-asso-
ciated hydrocephalus.
Respect for a patient’s autonomy
Respect for autonomy means that the physician accepts the 
choice made by a patient with decision-making capacity 
[26]. As patients with LM may have poor performance status 
and possibly neurocognitive sequelae [2], it is essential that 
the decision-making capacity of the patient is assessed early. 
Moreover, patients with LMD are generally terminally ill 
and comprise a particularly vulnerable group of individuals 
[27]. Some have previously suggested that decision-making 
capacity is impaired in patients who are nearing death, mak-
ing true informed consent particularly challenging to obtain 
[28, 29]. Furthermore, terminally ill patients often feel a 
sense of desperation stemming from unbearable symptoms 
and a hope to try any last effort to relieve suffering. Such 
desperation limits the voluntariness of any major decision-
making [28, 30].
Thus, before the various options for management are even 
discussed with the patient, the physician should assess his 
or her competence. If the patient demonstrates full decision-
making capacity, it is up to the team to clearly explain each 
of the above possible interventions, as well as their expected 
short-term and long-term consequences, so that the patient 
can make an informed decision. If a patient does not dem-
onstrate decision-making capacity, a proxy can be used to 
make decisions on their behalf [29, 31]. When no proxy 
has been named, these decisions are typically left to family 
members, physicians, and hospitals, who are expected to 
practice “substituted judgment,” i.e. to make a decision as 
the ill individual would have if they had been able to decide 
themselves [32].
Since each of the above options for LM-associated hydro-
cephalus will have different consequences for the patient’s 
life, the patient’s personal values should dictate the course-
of-action. Therefore, it is essential to assess the capacity of 
the patient and ensure that either the patient, if capable, or 
someone familiar with the patient’s belief systems be at the 
forefront of the decision-making process.
Studies have shown that patients’ values and religion may 
have particularly strong influences on end-of-life planning. 
For example, Hindus and Buddhists typically prefer dying at 
home, which may ultimately dictate what types of treatments 
they choose to receive [33]. To illustrate, if the placement 
of a shunt allows a patient to return home because they no 
longer have uncontrollable nausea requiring a nasogastric 
tube, that patient may choose to undergo shunting even if it 
means they will have to undergo a potentially risky surgical 
intervention.
Physicians treating patients with LM face challenging 
decisions. They should first prioritize establishing patient 
capacity, and once established, they should show utmost 
respect for the patient’s autonomy, rooted in his or her per-
sonal values, religious systems, and/or cultural paradigms. 
Through a shared decision-making approach that brings 
together medical information from the physician with the 
belief systems inherent to the patient, an optimal plan indi-
vidual to that patient can be reached.
Non‑maleficence
Non-maleficence means that physicians have the obligation 
to avoid harm to their patients [26, 34]. Omitting a standard-
of-care and exposing a patient to undue harm violates the 
principle of non-maleficence [34]. We believe that it is the 
responsibility of the physician and patient to work together 
to determine the course of action that minimizes harm to 
the patient while staying true to the patient’s own values, as 
described above.
Depending on the patients’ beliefs, he or she may favor 
relief in the short-term over long-term suffering, while 
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others may view this as burdensome prolonging of life (or 
even suffering). Such views on what course of action is “less 
bad” are often influenced by patient religion and culture. 
For example, in Roman Catholicism, “Natural Law,” is used 
to determine how to act morally in complex situations that 
may have both good and bad consequences [33]. Overall, 
an action with a negative consequence may be allowed if 
some greater good also occurs as a result of the action. For 
example, shortening of life may be permissible if it allows 
for alleviation of suffering. In the context of shunting in LM, 
such a belief system may prompt a patient to choose not to 
undergo intervention and opt for increasing pain medications 
instead, even if this means hastening death [33].
The theme once again emerges that in our case of lep-
tomeningeal metastases, the decision of whether or not to 
intervene is unclear. However, what is clear is that a discus-
sion with the patient and what he or she views as more or 
less “bad” should be undertaken to uphold the principle of 
non-maleficence and minimize harm to the patient, whether 
that be in the form of present-day or later suffering.
Beneficence
Per the principle of beneficence, physicians have an obli-
gation to benefit their patients and to balance these ben-
efits against any risks [26, 34]. Given the relative sparsity 
of data on quality-of-life measures following treatment for 
LM-associated hydrocephalus, upholding the principle of 
beneficence in such patients involves open discussion of all 
options, consideration of each patient’s individual progno-
sis, as well as the patient’s overall hopes and goals for any 
treatment. A patient with a KPS of 20 who is too weak to 
withstand another intervention, is unlikely to benefit from 
surgery. On the contrary, a young patient with a KPS of 70 
who wishes to play an active role in their children’s lives 
but is debilitated by headaches and nausea would likely ben-
efit from intervention. Beneficence, or what is best for one 
patient, may be different from what is best for another; thus, 
physicians should follow an individualized course for each 
patient that optimizes his or her health and comfort while 
minimizing any associated harms.
Justice
The fourth principle of biomedical ethics is justice, which 
pertains to ensuring fairness in how health benefits are dis-
tributed in society [26]. While this principle has typically 
been explored in the context of situations in which there is 
a scarcity of resources (e.g. organ transplantation, rationing 
of intensive care unit beds [35]), we think it is applicable in 
any medical setting.
Numerous studies have demonstrated that physicians 
may exhibit implicit bias against certain patient popula-
tions based on race, sex, or other characteristics, and that 
this implicit bias has been linked to poorer communication, 
lower quality care, and differential treatment of these groups 
[35–38]. While not directly related to the allocation of tan-
gible medical resources, such disparities and inequities in 
patient care violate the principle of justice.
Extrapolating this data to our case, it is important for 
physicians to maintain the same thoroughness in communi-
cation with all LM patients, regardless of race, sex, or edu-
cation-level. In fact, attention to justice may be even more 
critical in cases involving LM, where the pathophysiology 
is particularly complicated and may be difficult for physi-
cians to explain to laypersons. By leaving out information 
for some patients and thereby preventing those patients from 
having all the necessary data to make a decision, the physi-
cian would be violating the principle of justice. Thus, we 
believe that a key piece of the decision-making paradigm 
in how to manage LM-associated hydrocephalus requires 
the physician to spend ample time with and to equip each 
patient with a thorough enough understanding from which 
to make a decision.
Shared decision making
Ultimately, a decision as complex as how to manage LM-
associated hydrocephalus requires open discussion and 
collaboration amongst the patient, patient’s family/close 
friends, and physician. First and foremost, we believe that 
the physician needs to establish the decision-making capac-
ity of the patient. Once clear who the decision-maker for 
the patient will be (either the patient or a proxy), the physi-
cian should communicate all options to this individual and 
any other individuals whom the patient wishes. It is the 
responsibility of the physician to be complete and unbiased 
in presenting the objective risks and benefits of each option, 
tailored to that patient’s individual prognosis and disease 
presentation. Once this “factual” baseline is established, the 
physician should learn the patient’s values, cultural beliefs, 
and personal priorities. In situations where it may be helpful 
for the patient, religious or community leaders may also be 
involved to weigh in on the decision.
Recently, there has also been an increasing amount of 
evidence that supports the early involvement of palliative 
care teams in the care of cancer patients [39]. In those with 
terminal illnesses, these teams are specially trained to focus 
on caring for patients in a way that aligns with their val-
ues. Moreover, palliative care specialists, because of their 
interdisciplinary nature, are optimally positioned to facili-
tate communication among the many teams taking care of 
cancer patients [39]. Indeed, data from multiple randomized 
controlled trials have demonstrated that when palliative care 
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is integrated with routine oncological care, patients report 
improved quality-of-life, less aggressive end-of-life care, 
reduced symptom severity, and improved prognostic aware-
ness [38–42]. Based on these promising reports, palliative 
care physicians should be increasingly integrated into this 
shared decision-making model, as well.
With both the objective data set forth by the physician 
and the belief system of the patient made apparent, the two 
should work with teams like the palliative care doctors to 
re-assess the options and finally come to a shared decision. 
This shared decision should aim to respect the patient’s 
autonomous choices, while also staying true to the ethical 
medical principles of doing good and minimizing harm. By 
listening to and engaging with their patients, physicians can 
prioritize the patient’s dignity and comfort at a time of deep 
suffering and pain.
Conclusions
LM-associated hydrocephalus severely impacts length and 
quality of life. Given the paucity of quality-of-life and sur-
vival data, there is currently no consensus in the medical 
community regarding how best to manage hydrocephalus in 
these patients. Treatment options include (1) shunt place-
ment; (2) repeat lumbar punctures; (3) intraventricular res-
ervoir placement; (4) endoscopic third ventriculostomy; or 
(5) no acute intervention with a focus on pain management. 
We believe that the four ethical principles put forth by Beau-
champ and Childress (autonomy, non-maleficence, benefi-
cence, and justice) can aid in analysis of how to manage 
LM-associated hydrocephalus. Furthermore, we believe that 
the management of LM-hydrocephalus should hinge upon 
rigorous upholding of these principles as well a highly indi-
vidualized, patient-centered discussion of the management 
options. In this way, patients with a serious illness can safely 
and strongly live out whatever time they have left in a matter 
consistent with their personal and familial values.
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